School of Nursing, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Neurocrit Care. 2011 Aug;15(1):19-27. doi: 10.1007/s12028-011-9508-9.
Endothelin-1 (ET-1) is a potent vasoconstrictor implicated in the pathogenesis of vasospasm and delayed cerebral ischemia (DCI) in aneurysmal subarachnoid hemorrhage (aSAH) patients. The aim of this study was to investigate the relationship between cerebrospinal fluid (CSF) ET-1 levels and angiographic vasospasm and DCI.
Patients with aSAH were consented (n = 106). Cerebral vasospasm was determined by angiography. DCI was determined by transcranial Doppler (TCD) results and/or angiogram results with corresponding clinical deterioration. CSF ET-1 levels over 14 days after the initial insult was quantified by ELISA. ET-1 analysis included a group-based trajectory analysis and ET-1 exposure rate during 24, 48, and 72 h prior to, as well as 72 h post angiography, or clinical deterioration.
Trajectory analysis revealed two distinct groups of subjects with 56% of patients in the low ET-1 trajectory group (mean at day 1 = 0.31 pg/ml; SE = 0.04; mean at day 14 = 0.41 pg/ml; SE = 0.15) and 44% of patients in the high ET-1 trajectory group (mean at day 1 = 0.65 pg/ml; SE = 0.08; mean at day 14 = 0.61 pg/ml; SE = 0.06). Furthermore, we observed that ET-1 exposure rate 72 h before angiography and clinical spasm was a significant predictor of both angiographic vasospasm and DCI, whereas, ET-1 exposure after angiography and clinical spasm was not associated with either angiographic vasospasm or DCI.
Based on these results we conclude that ET-1 concentrations are elevated in a sub-group of patients and that the acute (72 h prior to angiography and clinical neurological deterioration), but not chronic, elevations in CSF ET-1 concentrations are indicative of the pathogenic alterations of vasospasm and DCI in aSAH patients.
内皮素-1(ET-1)是一种强效的血管收缩剂,与动脉瘤性蛛网膜下腔出血(aSAH)患者的血管痉挛和迟发性脑缺血(DCI)的发病机制有关。本研究旨在探讨脑脊液(CSF)ET-1水平与血管痉挛和 DCI 的关系。
征得 aSAH 患者同意(n = 106)。通过血管造影确定血管痉挛。通过经颅多普勒(TCD)结果和/或血管造影结果以及相应的临床恶化情况确定 DCI。通过 ELISA 定量测定初始损伤后 14 天内的 CSF ET-1 水平。ET-1 分析包括基于群组的轨迹分析以及在血管造影或临床恶化前 24、48 和 72 小时以及 72 小时内的 ET-1 暴露率。
轨迹分析显示,有 56%的患者处于低 ET-1 轨迹组(第 1 天的平均值为 0.31pg/ml;SE = 0.04;第 14 天的平均值为 0.41pg/ml;SE = 0.15),44%的患者处于高 ET-1 轨迹组(第 1 天的平均值为 0.65pg/ml;SE = 0.08;第 14 天的平均值为 0.61pg/ml;SE = 0.06)。此外,我们发现血管造影前 72 小时和临床痉挛时的 ET-1 暴露率是血管痉挛和 DCI 的重要预测指标,而血管造影后和临床痉挛时的 ET-1 暴露率与血管痉挛或 DCI 无关。
基于这些结果,我们得出结论,亚组患者的 ET-1 浓度升高,急性(血管造影和临床神经恶化前 72 小时)而非慢性 CSF ET-1 浓度升高提示 aSAH 患者的血管痉挛和 DCI 发病机制改变。